Interaction Checker

Tésamoréline : interactions médicamenteuses

Tésamoréline (Egrifta) présente 55 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 0 de niveau majeur, 23 de niveau modéré, 32 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions modérées (23)

  • Azélastine et fluticasoneantihistaminiqueModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • BéclométasonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • BétaméthasonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • BudésonidecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • Budésonide et formotérolcorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • CiclésonidecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • ClobétasolcorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • DéflazacortcorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • DésonidecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • FludrocortisonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • FlunisolidecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • FluocinonidecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • FluticasonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • Fluticasone et salmétérolcorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • HalobétasolcorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • HydrocortisonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • MéthylprednisolonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • MométasonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • Olopatadine et mométasoneantihistaminiqueModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • PrednisolonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • PrednisonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • TriamcinolonecorticoïdeModérée

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

Mentions mineures (32)

  • Acide valproïqueanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • BrivaracétamanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • Cannabidiol (sur ordonnance)anticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • CiclosporineimmunosuppresseurMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • ClobazambenzodiazépineMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • ClonazépambenzodiazépineMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • Divalproate de sodium (valproate)anticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • ÉthosuximideanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • Ézétimibe et simvastatinestatineMineure

    Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see Clinical Pharmacology ( 12.3 )] . (notice Tésamoréline, Interactions médicamenteuses)

  • FelbamateanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • GabapentineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • LacosamideanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • LamotrigineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • LévétiracétamanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • MésuximideanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • PérampanelanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • PrégabalineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • RufinamideanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • SimvastatinestatineMineure

    Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see Clinical Pharmacology ( 12.3 )] . (notice Tésamoréline, Interactions médicamenteuses)

  • TiagabineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • VigabatrineanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

  • ZonisamideanticonvulsivantMineure

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (notice Tésamoréline, Interactions médicamenteuses)

Vérifiez Tésamoréline avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.